about
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cellsGeneration and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast.SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapyAntitumor activity of mutant bacterial cytosine deaminase gene for colon cancer.A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKsHighly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug.Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells.Gene therapy vector design strategies for the treatment of cancer.Thymic epithelial requirement for γδ T cell development revealed in the cell ablation transgenic system with TSCOT promoterSimian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophagesTumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.The immune boundaries for stem cell based therapies: problems and prospective solutions.Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues.Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.Expression of Therapeutic Gene FCU1 Sensitizes Pancreatic Cancer Cells to 5-Fluorocytosine and Enhances the Cytotoxic Effect of 5-Fluorouracil.A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models.Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines.Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity.Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography.A preliminary step of a novel strategy in suicide gene therapy with lentiviral vector.Gene therapy of liver cancer.VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy.Modulated nucleoside kinases as tools to improve the activation of therapeutic nucleoside analogues.Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy.Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na131I/5-FC on human thyroid cancer.Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.
P2860
Q24815069-14487671-06CE-45BC-A36F-54432BCED3DAQ28263579-3A843C59-3191-41F8-A2CE-172CFF18CB7CQ33368449-C64E77FD-F61B-4E35-8738-6C07923F9C34Q34695978-49F17DDD-EB54-47B0-98A0-D341B9D83ADBQ35082459-AB148255-C0FC-4521-9DCB-FB559AFB6BD3Q35085995-5B315610-1C0A-4721-98EB-07C76448E052Q35145614-8AEEF585-7A0C-4C6D-981B-FE4E72383E04Q35695549-85E329F5-4A9B-43E5-BF2F-FF738B0673D9Q36085539-1D2EEB26-6FC9-40A0-8317-803D5D085386Q36279293-CABE75F3-6046-48FB-86BE-FD136FEF1E8CQ36429492-CD58BAA4-B22E-4FDB-AAA3-00C8528A6FCBQ36474503-7922AAFD-A5CD-4A6E-B0B0-37C96A9CB0F3Q36944674-B53E3A01-D854-499A-98E0-A10B3FD13CE9Q37012358-24645DCC-5265-4ACA-B33B-F64F1AA8C682Q37310625-8385CC60-87AE-4BBC-B959-89E251D81887Q37431500-A25F827A-D920-4BED-81A7-B45CF3837581Q37603380-ABD41F15-69FB-4AA3-B524-879173DD5B8BQ38736690-9D3713D2-4BCB-40CF-AB8A-DDE55C93A2FBQ38870602-73C67906-AEDC-4C2F-9A98-2B945F4001C5Q39195649-3C764F5F-2DDA-4EEF-B27C-691890F69BD9Q39296297-F019D567-AD46-4130-9F27-B7A54B66060AQ40388169-81730D84-6ED5-4933-BEB5-5EA7907F37D5Q40442900-61A389F4-10AF-4532-9B12-FC9D392ACEBDQ40481759-8BC37F3F-F3E1-4740-9664-4BF1DF7F2016Q41965164-EC935DCE-A9C6-4AB5-B186-39F6E9634727Q42726362-9A730C07-5A19-4996-A061-0A8779DF15ECQ44796764-D0E4003C-1649-48D0-BFE3-77080999FAF0Q45211779-11AE77D7-2A04-4A04-A319-71C898096B3CQ45861399-D2E12B21-7672-428A-97BF-95093D7C078FQ48360437-2845A6C6-65F2-4C9E-81D9-961BA62B52DCQ49207200-CE35523A-4178-4478-8E71-8F77CA0FCB1FQ51467919-4DECE178-17A9-4B7C-B90F-49A68E621003
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current progress in suicide gene therapy for cancer.
@ast
Current progress in suicide gene therapy for cancer.
@en
Current progress in suicide gene therapy for cancer.
@nl
type
label
Current progress in suicide gene therapy for cancer.
@ast
Current progress in suicide gene therapy for cancer.
@en
Current progress in suicide gene therapy for cancer.
@nl
prefLabel
Current progress in suicide gene therapy for cancer.
@ast
Current progress in suicide gene therapy for cancer.
@en
Current progress in suicide gene therapy for cancer.
@nl
P2093
P921
P1476
Current progress in suicide gene therapy for cancer.
@en
P2093
F Charles Brunicardi
Kazuyuki Yazawa
William E Fisher
P2888
P304
P356
10.1007/S00268-002-4053-5
P577
2002-04-15T00:00:00Z
P6179
1001468017